Third patient dosed in Initial Dose Cohort in Ph 1 CER-1236 AML Trial
Chris Ehrlich, CERo Therapeutics Chief Executive Officer, stated, “Dosing the third and final planned patient in the starting dose cohort represents an important milestone for CERo. At this lowest dose level, we have observed pharmacokinetic data showing cell expansion, and with IRB approval and customary FDA submission, the protocol has been modified to increase dosing potential within each cohort by allowing for a second infusion in the same subject. While early, these changes are expected to provide valuable information as we prepare to move to higher doses, which are designed to more fully explore the potential for enhanced biological activity. We remain encouraged by the progress of the study and deeply grateful to the patients, investigators, and our team who have made this advancement possible.”
Share:
More News
“These data underscore gotistobart’s potential to redefine treatment for patients with hard-to-treat squamous NSCLC whose disease has progressed after initial therapy and who face limited options,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “In second- and later lines of treatment, the clinical relevance of novel
“The collaboration with Ratio represents an exciting opportunity to explore the potential of novel radiopharmaceutical approaches designed to address the complexity and heterogeneity of cancer,” said Ben Hickey, President of RayzeBio. “The combination of our respective technologies and complementary development expertise creates a strong foundation for generating a novel differentiated
“We believe these results mark a potentially important step forward in the treatment of EGFR exon 20 insertion mutation-positive non-small cell lung cancer,” said Fabio Benedetti, MD, Global Chief Medical Officer, Taiho Pharmaceutical. “To address the unmet medical needs of patients and their families, we will continue working closely with
“Recent clinical data validated KAT6 as a targetable mechanism in the treatment of HR+/HER2- breast cancer, including those with actionable mutations,” stated Charles Morris, MBChB, MRCP, Chief Medical Officer of Prelude. “Dual KAT6A/B inhibitors, however, demonstrated overlapping toxicities with current backbone therapies that may limit the utility in earlier lines